A Phase 2 interventional study of Carboplatin and Nivolumab in Lung Cancer, sponsored by Massachusetts General Hospital. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-04.
Sponsored by Massachusetts General Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 156 studies testing carboplatin in Lung Neoplasms — 9 open to participants now, 18 under way, 3 of them phase 3. Carboplatin · Lung Neoplasms.
Among the 156 studies testing carboplatin in Lung Neoplasms, this one is the 119th largest by enrollment of the 137 interventional ones that give a count, is one of 5 that started in 2017, is one of 102 in phase 2, and was the 133rd registered.
5,427 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →9 of the 156 studies testing carboplatin in Lung Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Latin American Cooperative Oncology Group · Sites in Brazil
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 70+
Centre Leon Berard · Sites in France, Reunion
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
By country, each count listing its studies:
Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →
Of the 995 Lung Neoplasms studies recruiting now, 684 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
156 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 115 · Phase 3 27 · Phase 4 2
First in 1996; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 60 across 3,660 interventional studies indexed under Lung Neoplasms.
Median enrollment 49 across the 137 interventional studies. Of the 113 that completed or were terminated, 48 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 156 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,590 studies on the registry; 447 are open to participants now.
Of its 223 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
49 studies in Lung Neoplasms by Massachusetts General Hospital: 17 open now, 20 under way, none of them phase 3. Of 26 finished, 12 (46%) have results posted.
Among the 49 studies in Lung Neoplasms by Massachusetts General Hospital, this one is the 38th largest by enrollment of the 43 interventional ones that give a count, is one of 7 that started in 2017, is one of 10 in phase 2, and was the 22nd registered.
Massachusetts General Hospital’s Lung Neoplasms studies by the year they started, since 1993.
2 of the studies testing carboplatin in Lung Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03793179Phase 3National Cancer Institute (NCI)Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | 2027-09-30 |
| NCT05358548Rutgers, The State University of New JerseyATATcH Alternating Treatment Plans for Advanced Cancer | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 156 studies testing carboplatin in Lung Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Massachusetts General Hospital’s 49 in Lung Neoplasms:
This tab as a report to print or save as PDF → With an account.
This research study is studying a drug intervention as a possible treatment for lung cancer.
The drugs involved in this study are:
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease.
The FDA (the U.S. Food and Drug Administration) has approved Nivolumab as a treatment for other types of cancers including lung cancer. However, the combination of Nivolumab with other drugs (such as those being tested in this study) has not been approved by the FDA as a treatment for this type of lung cancer.
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the drug Nivolumab in combination with standard of care chemotherapies, or in combination with Ipilimumab. Nivolumab and Ipilimumab are antibodies (a type of human protein) that are being tested to see if they will allow the body's immune system to work against tumor cells. This study is being done to see if Nivolumab and Ipilimumab, or Nivolumab and chemotherapy drugs (Carboplatin and Pemetrexed), are more effective against cancer when administered together.
These drugs are given as infusions. They are designed to "boost" the immune system's ability to suppress or kill cancer cells that are foreign to the human body.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
or cytologically confirmed advanced (stage IIIB or IV) non-small-cell lung cancer (NSCLC).
Prior treatment with appropriate tyrosine kinase inhibitors (TKIs) as follows:
Prior systemic chemotherapy requirements are as follows:
Screening laboratory values must meet the following criteria:
Serum creatinine ≤ 1.5 x or calculated using Cockcroft-Gault formula ≥ 50 mL/min
Females of (defined as a sexually mature woman who has not undergone a hysterectomy or bilateral oophorectomy or has not been naturally for at least 24 consecutive months) must:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
Drug: Nivolumab · Drug: Ipilimumab
Nivolumab administered intravenously every 2 weeks Ipilimumab administered intravenously every 6 weeks
Drug: Nivolumab · Drug: Ipilimumab
Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
Drug: Carboplatin · Drug: Nivolumab · Drug: pemetrexed
Nivolumab administered intravenously every 3 weeks Carboplatin administered intravenously every 3 weeks Pemetrexed administered intravenously every 3 weeks
Drug: Carboplatin · Drug: Nivolumab · Drug: pemetrexed
Chemotherapy
Also known as: Paraplatin
will allow the body's immune system to work against tumor cells
Also known as: Opdivo
Chemo therapy
Also known as: Alimta
will allow the body's immune system to work against tumor cells
Also known as: Yervoy
Objective Response Rate (ORR), Presented in Numbers of Participants
Complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to approximately 2 years
Disease Control Rate (DCR), Presented in Numbers of Participants
The number of patients that achieved either complete response (CR), partial response (PR), or stable disease (SD) per RECIST version 1.1 * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. * Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.
Time frame: Up to approximately 2 years
Progression Free Survival (PFS)
Time from initiation of the study drugs to progression or death, whichever occurs first. Disease progression was assessed via RECIST 1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note:the appearance of one or more new lesions is also considered progression). Confidence Intervals (CIs) were calculated using the Kaplan Meier (KM) method
Time frame: From the start of treatment until disease progression or death due to any cause, up to approximately 2 years
Overall Survival (OS)
Time from initiation of the study drugs to date of death due to any cause. CIs are the KM estimate CIs.
Time frame: From the start of treatment until death due to any cause, up to approximately 2 years
Duration Of Response
Time from the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. * Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note:the appearance of one or more new lesions is also considered progression).
Time frame: From the first documented response until disease progression or death, up to approximately 2 years
| Milestone | Nivolumab Plus Ipilimumab EGFR | Nivolumab Plus Ipilimumab ALK | Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive | Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive |
|---|---|---|---|---|
| Started | 3 | 1 | 4 | 1 |
| Completed | 3 | 1 | 4 | 1 |
| Not completed | 0 | 0 | 0 | 0 |
Complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Participants | Nivolumab Plus Ipilimumab EGFR | Nivolumab Plus Ipilimumab ALK | Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive | Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive |
|---|---|---|---|---|
| Objective Response Rate (ORR), Presented in Numbers of Participants | 0 | 0 | 1 | 1 |
The number of patients that achieved either complete response (CR), partial response (PR), or stable disease (SD) per RECIST version 1.1 * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. * Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum diameters while on study.
| Participants | Nivolumab Plus Ipilimumab EGFR | Nivolumab Plus Ipilimumab ALK | Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive | Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive |
|---|---|---|---|---|
| Disease Control Rate (DCR), Presented in Numbers of Participants | 0 | 0 | 3 | 1 |
Time from initiation of the study drugs to progression or death, whichever occurs first. Disease progression was assessed via RECIST 1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note:the appearance of one or more new lesions is also considered progression). Confidence Intervals (CIs) were calculated using the Kaplan Meier (KM) method
| months | Nivolumab Plus Ipilimumab EGFR | Nivolumab Plus Ipilimumab ALK | Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive | Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive |
|---|---|---|---|---|
| Progression Free Survival (PFS) | 1.3 (0.6 to 1.4) | 0.7 (NA to NA) | 4.65 (1.2 to 8.4) | 2.8 (NA to NA) |
Time from initiation of the study drugs to date of death due to any cause. CIs are the KM estimate CIs.
| months | Nivolumab Plus Ipilimumab EGFR | Nivolumab Plus Ipilimumab ALK | Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive | Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive |
|---|---|---|---|---|
| Overall Survival (OS) | 22.3 (2.6 to 23.7) | 7.6 (NA to NA) | 7.75 (2.1 to 16.2) | 15.9 (NA to NA) |
Time from the first documentation of objective tumor response (CR or PR) to the first documentation of objective tumor progression or death due to any cause, whichever occurs first * Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. * Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. * Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note:the appearance of one or more new lesions is also considered progression).
| months | Nivolumab Plus Ipilimumab EGFR | Nivolumab Plus Ipilimumab ALK | Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive | Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive |
|---|---|---|---|---|
| Duration Of Response | NA (NA to NA) | NA (NA to NA) | 0.9 (NA to NA) | 1.4 (NA to NA) |
Collected over From the start of treatment until 30 days after the end of treatment, up to approximately 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nivolumab Plus Ipilimumab EGFR | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Nivolumab Plus Ipilimumab ALK | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) |
| Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive | 2/4 (50%) | 3/4 (75%) | 4/4 (100%) |
| Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Event | Nivolumab Plus Ipilimumab EGFR | Nivolumab Plus Ipilimumab ALK | Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive | Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive |
|---|---|---|---|---|
| DyspneaRespiratory, thoracic and mediastinal disorders | 0/3 | 1/1 | 0/4 | 0/1 |
| Blood bilirubin increaseInvestigations | 0/3 | 0/1 | 1/4 | 0/1 |
| Skin infectionInfections and infestations | 0/3 | 0/1 | 1/4 | 0/1 |
| AspirationRespiratory, thoracic and mediastinal disorders | 0/3 | 0/1 | 1/4 | 0/1 |
| SeizureNervous system disorders | 0/3 | 0/1 | 1/4 | 0/1 |
| AnemiaBlood and lymphatic system disorders | 0/3 | 0/1 | 1/4 | 0/1 |
| Neutrophil count decreaseBlood and lymphatic system disorders | 0/3 | 0/1 | 1/4 | 0/1 |
| VertigoEar and labyrinth disorders | 0/3 | 0/1 | 1/4 | 0/1 |
| FallInjury, poisoning and procedural complications | 0/3 | 0/1 | 1/4 | 0/1 |
| Event | Nivolumab Plus Ipilimumab EGFR | Nivolumab Plus Ipilimumab ALK | Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive | Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive |
|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/3 | 0/1 | 2/4 | 1/1 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 2/3 | 0/1 | 1/4 | 1/1 |
| AnxietyPsychiatric disorders | 0/3 | 0/1 | 0/4 | 1/1 |
| FatigueGeneral disorders | 2/3 | 0/1 | 4/4 | 0/1 |
| AnemiaBlood and lymphatic system disorders | 0/3 | 0/1 | 3/4 | 0/1 |
| AnorexiaMetabolism and nutrition disorders | 2/3 | 0/1 | 1/4 | 0/1 |
| PainGeneral disorders | 1/3 | 0/1 | 2/4 | 0/1 |
| Aspartate aminotransferase increasedInvestigations | 1/3 | 0/1 | 2/4 | 0/1 |
| NauseaGastrointestinal disorders | 1/3 | 0/1 | 2/4 | 0/1 |
| VomitingGastrointestinal disorders | 1/3 | 0/1 | 2/4 | 0/1 |
| Age, Categorical(Participants) | Nivolumab Plus Ipilimumab EGFR | Nivolumab Plus Ipilimumab ALK | Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive | Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 1 | 2 | 1 | 5 |
| >=65 years | 2 | 0 | 2 | 0 | 4 |
| Sex: Female, Male(Participants) | Nivolumab Plus Ipilimumab EGFR | Nivolumab Plus Ipilimumab ALK | Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive | Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive | Total |
|---|---|---|---|---|---|
| Female | 2 | 1 | 1 | 0 | 4 |
| Male | 1 | 0 | 3 | 1 | 5 |
| Race (NIH/OMB)(Participants) | Nivolumab Plus Ipilimumab EGFR | Nivolumab Plus Ipilimumab ALK | Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive | Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 2 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 2 | 1 | 2 | 1 | 6 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Nivolumab Plus Ipilimumab EGFR | Nivolumab Plus Ipilimumab ALK | Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive | Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive | Total |
|---|---|---|---|---|---|
| United States | 3 | 1 | 4 | 1 | 9 |
| Treatment Regimen Received(Participants) | Nivolumab Plus Ipilimumab EGFR | Nivolumab Plus Ipilimumab ALK | Nivolumab + Carboplatin + Pemetrexed With EGFR Chemo Naive | Nivolumab + Carboplatin + Pemetrexed ALK Chemo Naive | Total |
|---|---|---|---|---|---|
| Count of participants | 3 | 1 | 4 | 1 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2017 to primary completion in Aug 2019, 20 months.
Results were first posted in Oct 2020, 1 year 2 months after primary completion.
Of 286 non-industry phase 2 interventional studies under Lung Neoplasms, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 113. This study's 20 months is below that.
Counting every sponsor, half of 363 studies reached it within 65 months; a quarter within 34 and three quarters within 102.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carboplatin · Nivolumab · Pemetrexed · Ipilimumab
Massachusetts General Hospital →